Month: August 2021

COLLINGWOOD, Ontario, Aug. 05, 2021 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (“Limestone”) (TSXV:BOAT) – owner and builder of Aquasport Boats, Limestone® Boats and Boca Bay Boats – recently announced a new flagship model for Aquasport, a new website for the Aquasport brand, and delivery of the first Limestone® production boat. The Aquasport 3000CC center console is their largest model to date, becoming the latest flagship. It will make its official debut this summer and be available for order with shipments commencing this fall. “The new model showcases a flared bow and deep freeboard that Aquasport’s saltwater models are known for, all on a beautifully-running hull for an incredible ride and performance,” said Limestone CEO Scott Hanson. “Being stable, dry, and sure-footed in just about any chop, this model still...

Kirkland, Washington & Parsippany, New Jersey, Aug. 05, 2021 (GLOBE NEWSWIRE) — Pivotal Commware, Inc., a global leader in 5G mmWave smart infrastructure products, and CommAgility, a Wireless Telecom Group (NYSE American: WTT) brand and award-winning software supplier to 4G and 5G networks, today announced the integration of CommAgility’s physical layer software into Pivotal’s Echo 5G™ and Pivot 5G™ repeaters designed for delivering superior broadband experiences to more 5G mmWave subscribers at less cost. Echo is a low-profile, glass-attached repeater installed by subscribers to facilitate in-building penetration of mmWave signals from 5G small cells. The Pivot outdoor network repeater extends mmWave signals beyond the base station’s line-of-sight so carriers can increase coverage for less cost. Other members of Pivotal’s...

Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancer PORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1 antibodiesWESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) — Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors. Preclinical data for PORT-2 demonstrated...

Conference Call on Thursday, August 12th, 2021 at 3:00pm EST / 12:00pm PST San Francisco, CA, Aug. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its second quarter 2021 financial results on Thursday, August 12th, 2021 at 3:00pm EST / 12:00pm PST. The second quarter 2021 financial results press release will be issued premarket the morning of Thursday, August 12th, 2021. Teleconference Date/Time Thursday, August 12th, 2021 at 3:00pm EST / 12:00pm PST Teleconference and Webcast Information To participate, please call 1 (877) 317-6789...

GREENWICH, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) today announced the following net asset value (“NAV”) estimate as of July 31, 2021.Management’s unaudited estimate of the range of the NAV per share of our common stock as of July 31, 2021 is between $6.68 and $6.78. This estimate is not a comprehensive statement of our financial condition or results for the month ended July 31, 2021. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ending September 30, 2021 may differ materially from this estimate, which is given only as of July 31, 2021.As of July 31, 2021, the Company had approximately...

WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has successfully reached its target of 20 activated clinical trial sites in the Phase 2b portion of the VOICE trial. Validive® is a small, easy-to-use mucobuccal tablet that can be self-administered in the patient’s home setting. The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC). There is no FDA-approved preventative or treatment option for the estimated >40,000 OPC patients in the US annually who are at-risk...

Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003. This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep’s lead product candidate eftilagimod alpha (efti or IMP321). INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and anti-PD-1 therapy. The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in...

HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology Intended to serve as one of the technological cornerstones for the recently announced HTG Therapeutics Business Unit A third white paper highlighting the HTG Transcriptome Panel’s design, performance, and broad applicability now available TUCSON, Ariz., Aug. 05, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the commercial launch and immediate availability of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology, in the U.S. and Europe. While HTG received its first orders for this product from Early Adopter Program (EAP) collaborators in June...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, and provided a corporate update. “We continue to make progress in our complement and hemostasis programs. In complement, we are advancing the development of our SQ enhanced CFI development candidate, CB 4332, where we screened the first patient in our natural history study for CFI deficiency (“ConFIrm”). We also recently disclosed new proteases from our ProTUNE™; C3b-C4b degrader and ImmunoTUNE™; C3a-C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “With the initiation of the ConFIrm study and...

New Leadership, New Identity, New Company, New Partners DENVER, Aug. 05, 2021 (GLOBE NEWSWIRE) — authID.AI (www.authid.ai) [OTCQB:AUID] today announced its results for the second quarter ended June 30, 2021. The Company, previously known as Ipsidy, made strategic changes in its branding, leadership and board of directors, and continued to expand its channel partner network. The authID platform eliminates the need for passwords by delivering secure biometric identity proofing and authentication solutions to a broad array of verticals including finance, healthcare, sharing economy, online gaming and other large data-sensitive industries. The strengthened firm is poised to capture greater share of the growing market for password alternatives and cyber threat solutions. Financial Results for the Three Months and Six Months Ended June...